Patricio de Hoyos Zambrano, MD
Pulmonary Disease · San Antonio, TXNPI 1396006680
Payments from drug & device makers
Across 290 payments — averaging $38.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$4K
- Imbed Biosciences Inc.$2K
- GSK$1K
- AstraZeneca$849
- Boehringer Ingelheim$493
- Mylan Specialty L.p.$446
- plus $3K from 27 others
What the payments were for
- Travel & lodging$1,85616%
- Food & beverage$9,40684%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 34 | $3,746 |
| Imbed Biosciences Inc. | 22 | $1,994 |
| GSK | 67 | $1,051 |
| AstraZeneca | 41 | $849 |
| Boehringer Ingelheim | 20 | $493 |
| Mylan Specialty L.p. | 19 | $446 |
| Baxter Healthcare | 7 | $378 |
| Olympus America Inc. | 6 | $301 |
| Regeneron Healthcare Solutions, Inc. | 7 | $201 |
| Myriad Genetic Laboratories, Inc. | 2 | $189 |
| Grifols USA, LLC | 7 | $185 |
| Amgen | 8 | $151 |
| Abiomed | 1 | $147 |
| Sanofi | 6 | $146 |
| Inari Medical, Inc. | 1 | $123 |
| Tactile Systems Technology Inc | 6 | $106 |
| Electromed, Inc. | 8 | $101 |
| Medtronic | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $78 |
| Philips North America LLC | 4 | $73 |
| Insmed, Inc. | 3 | $68 |
| United Therapeutics Corporation | 3 | $66 |
| Johnson & Johnson | 1 | $38 |
| Verona Pharma, Inc. | 2 | $37 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Viatris Specialty LLC | 1 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Gilead | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Bayer | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPHYR ENDOBRONCHIAL VALVE$2,980
- CHARTIS CATHETER$1,147
- PULMONX CHARTIS TABLET CONSOLE$1,147
- ZEPHYR DELIVERY CATHETER$1,147
- TISSEEL$279
- Impella$147
- Respiratory Needles$135
- TEZSPIRE$126
- FLOWTRIEVER CATHETER, S$123
- CT THROMBECTOMY SYSTEM KIT$123
- OFEV$111
How this compares
$11,261 in reported general payments places this provider in the 75th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 14 | $180,814 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 117 | $106,032 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 81 | $57,893 |
| TezspireTezepelumab-Ekko | 12 | $46,252 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 61 | $34,202 |
| Spiriva RespimatTiotropium Bromide | 35 | $34,158 |
| EliquisApixaban | 21 | $15,830 |
| SymbicortBudesonide/Formoterol Fumarate | 51 | $12,123 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 160 | $5,407 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $3,146 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $3,029 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $2,929 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $1,571 |
| Azithromycin | 91 | $1,283 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 20 | $1,170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $493 | $249,174110 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $849 | $116,268144 claims |
| GSKTrelegy Ellipta | $1,051 | $106,032117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in San Antonio
- Charles AndrewsSan Antonio$17M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
- John HolcombSan Antonio$1.7M
- David MarksSan Antonio$1.3M
- Anoop NambiarSan Antonio$840K
- Rodolfo Estrada AnzuetoSan Antonio$324K
- Ali AbediSan Antonio$269K
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.